INmune Bio and QCi Apply Quantum Computing to XPro Research
Oct 14, 2026
Life Sciences
Insilico Medicine and SK Biopharmaceuticals Sign $2.5 Billion AI Drug Discovery Deal
Jun 23, 2026
Insilico Medicine and SK Biopharmaceuticals have entered a research and development collaboration worth up to $2.5 billion to develop drug candidates for neuroimmune disorders using Insilico’s AI platform.
Insilico Medicine and SK Biopharmaceuticals have entered a research and development collaboration to discover drug candidates for neuroimmune disorders, announced in a press release. The agreement, revealed at the BIO 2026 International Convention, has a potential total value exceeding 2.5 billion dollars.
Under the partnership, Insilico will use its Pharma.AI platform for target validation, generative chemistry, and molecule optimization. SK Biopharmaceuticals will oversee late-stage development and commercialization of resulting therapies targeting neuroimmune conditions affecting the central nervous system.
Insilico will receive up to 18 million dollars in upfront and near-term milestone payments, with additional payments tied to development, regulatory, and commercial milestones. The company will also earn single-digit royalties on net sales once products reach the market.
The collaboration aims to accelerate the discovery of therapies for neuroinflammatory, neurodegenerative, and rare neurological disorders by combining Insilico’s AI-based research capabilities with SK Biopharmaceuticals’ clinical expertise.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly, AI Funding Brief or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 13 Bracco and Avicenna.AI win FDA clearance for AI that flags brain aneurysms on CT scans Nov 13 Zus Health raises $33 million to build the data layer for healthcare AI Nov 13 Google DeepMind releases AlphaGenome 2 to predict DNA variant effects in specific cell types Nov 13 Taiwan hospital accelerator T+ MedIC names AI ECG and CT screening tools as first winners Nov 13 Sheinbaum meets OpenAI president Greg Brockman on AI in Mexican healthcareMore from Funding
Nov 13 Peter Sarlin's PostScriptum takes majority stake in Finnish AI deployment firm Brillian Nov 13 MISTT raises £5 million to build a space-and-time data layer for AI and autonomous systems Nov 13 Zus Health raises $33 million to build the data layer for healthcare AI Nov 12 Inveniam acquires Docugami, the document AI startup of XML pioneer Jean Paoli Nov 12 Huang's exit puts extra pressure on Anthropic's IPO next week, investors tell FortuneFree newsletter
Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
The Hackett Group
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Isomorphic Labs Seeks $5 Billion at $50 Billion Valuation
Nov 05, 2026
Funding
Zealand Pharma signs AI obesity drug deal worth up to $1.2 billion
Oct 15, 2026
Biotech
Switchpoint Bio raises $5.3 million for AI epigenomics platform
Nov 11, 2026
Funding
BioMap Announces 11 AI Life Science Collaborations
Nov 12, 2026
Life Sciences
ALLOX Raises $10.5 Million for AI Drug Discovery Platform
Oct 29, 2026
Funding
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.